Hoffbrand's Essential Haematology

A. Victor Hoffbrand, David P. Steensma

• Publisher: Wiley-Blackwell
• Year: 2019
• Print ISBN: 9781119495901
• eBook ISBN: 9781119495956
• Edition: 8
• Topic: Medicine
• Subtopic: Hematology

The new and fully updated edition of the definitive haematology textbook for undergraduate and postgraduate students and trainees

Hoffbrand's Essential Haematology is widely regarded as the most authoritative introduction to the subject available, helping medical students and trainee doctors understand the essential principles of modern clinical and laboratory haematology for nearly four decades. Now in its eighth edition, this market-leading textbook introduces the formation and function of blood cells and the diseases that arise from dysfunction and disruption of these processes.

Beautifully presented with over 300 stunning colour illustrations, the new edition has been thoroughly updated to reflect recent advances in knowledge of the pathogenesis of blood diseases and their diagnosis and treatment. This new text:

• Describes disorders and diseases of the blood such as the various anaemias and white cell disorders, leukaemias, lymphomas and myeloma, as well as bleeding and thrombotic disorders
• Incorporates the latest World Health Organization (WHO) classification of haematological neoplastic diseases
• Reviews contemporary application of multiparameter flow cytometry, DNA sequencing and other technologies in evaluating patients with suspected haematological disease
• Discusses the therapeutic use of chimeric antigen T-cells, mono- and bi-specific monoclonal antibodies, inhibitors of intracellular signalling pathways and direct orally acting anticoagulants
• Includes sections on blood transfusion and the haematological aspects of systemic diseases, pregnancy and the neonate

Hoffbrand's Essential Haematology is a vital resource for all students and trainees, and a valuable reference for practicing specialists wishing to update their knowledge.

CHAPTER 1
Haemopoiesis

Key topics

• Site of haemopoiesis
• Haemopoietic stem and progenitor cells
• Bone marrow stroma
• The regulation of haemopoiesis
• Haemopoietic growth factors
• Growth factor receptors and signal transduction
• Adhesion molecules
• The cell cycle
• Transcription factors
• Epigenetics
• Apoptosis

This first chapter is concerned with the general aspects of blood cell formation (haemopoiesis). The processes that regulate haemopoiesis and the early stages of formation of red cells (erythropoiesis), granulocytes and monocytes (myelopoiesis) and platelets (thrombopoiesis) are also discussed.

Site of haemopoiesis

In the first few weeks of gestation, the embryonic yolk sac is a transient site of haemopoiesis called ‘primitive haemopoiesis’. However, ‘definitive haemopoiesis’ derives from a population of stem cells first observed on the aorta-gonads-mesonephros (AGM) region of the developing embryo. These common precursors of endothelial and haemopoietic cells are called haemangioblasts and are believed to seed the liver, spleen and bone marrow.

From 6 weeks until 6–7 months of fetal life, the liver and spleen are the major haemopoietic organs and continue to produce blood cells until about 2 weeks after birth (Table 1.1; see Fig. 7.1b). The placenta also contributes to fetal haemopoiesis. The bone marrow is the most important site from 6–7 months of fetal life. During normal childhood and adult life, the marrow is the only source of new blood cells. The developing cells are situated outside the bone marrow sinuses; mature cells are released into the sinus spaces, the marrow microcirculation and so into the general circulation.

In infancy all the bone marrow is haemopoietic, but during childhood and beyond there is progressive fatty replacement of marrow throughout the long bones, so that in adult life haemopoietic marrow is confined to the central skeleton and proximal ends of the femurs and humeri (Table 1.1). Even in these active haemopoietic areas, approximately 50% of the marrow consists of fat in the middle-aged adult (Fig. 1.1). The remaining fatty marrow is capable of reversion to haemopoiesis and in many diseases there is also expansion of haemopoiesis down the long bones. Moreover, in certain disease states the liver and spleen can resume their fetal haemopoietic role (‘extramedullary haemopoiesis’).

Table 1.1 Dominant sites of haemopoiesis at different stages of development.

Fetus	0–2 months (yolk sac)
	2–7 months (liver, spleen)
	5–9 months (bone marrow)
Infants	Bone marrow (practically all bones); dwindling post-parturition contribution from liver/spleen that ceases in the first few months of life
Adults	Vertebrae, ribs, sternum, skull, sacrum and pelvis, proximal ends of femur

Figure 1.1 Normal bone marrow trephine biopsy (posterior iliac crest). Haematoxylin and eosin stain; approximately 50% of the intertrabecular tissue is haemopoietic tissue and 50% is fat.

Haemopoietic stem and progenitor cells

Haemopoiesis starts with a pluripotential stem cell that can self-renew by asymmetrical cell division, but also gives rise to the separate cell lineages. These cells are able to repopulate a bone marrow from which all stem cells have been eliminated by lethal irradiation or chemotherapy. Self-renewal and repopulating ability define the haemopoietic stem cell (HSC). HSCs are rare, perhaps 1 in every 20 million nucleated cells in bone marrow. Newer DNA sequencing techniques suggest that a typical adult has approximately 50 000 HSCs.

HSCs are heterogeneous, with some able to repopulate a bone marrow for more than 16 weeks, called long-term HSCs, while others, although able to produce all haemopoietic cell types, engraft only transiently for a few weeks and are called short–term HSCs. Although the exact cell surface marker phenotype of the HSC is still unknown, on immunological testing these cells are positive for the marker Cluster of Differentiation 34 (CD34⁺) and negative for CD38⁻ and for cell lineage-defining markers (Lin⁻). Morphologically, HSCs have the appearance of a small or medium-sized lymphocyte (see Fig. 23.3). The cells reside adjacent to osteoblasts or to endothelial cells of sinusoidal vessels in endosteal or vascular ‘niches’, where they are surrounded by stromal cells, with which they interact in numerous ways. The niches also contain sympathetic nerve endings.

Cell differentiation occurs from the stem cells via committed haemopoietic progenitors, which are restricted in their developmental potential (Fig. 1.2). The existence of the separate progenitor cells can be demonstrated by in vitro culture techniques. Stem cells and very early progenitors are assayed by culture on bone marrow stroma as long-term culture- initiating cells, whereas late progenitors are generally assayed in semi-solid media. As examples, in the erythroid series progenitors can be identified in special cultures as burst-forming units (BFU-E, describing the ‘burst’ with which they form in culture) and colony-forming units (CFU-E; Fig 1.2); the mixed granulocyte/monocyte progenitor is identified as a colony-forming unit-granulocyte/monocyte (CFU-GM) in culture. Megakaryocytes form from the CFU-Meg.

Figure 1.2 Diagrammatic representation of the bone marrow pluripotent stem cells (haemopoietic stem cells, HSC) and the cell lines that arise from them. A megakaryocytic/erythroid progenitor (MkEP) and a mixed lymphoid/myeloid progenitor are formed from the pluripotent stem cells. Each gives rise to more differentiated progenitors. The MkEP divides into erythroid and megakaryocyte progenitors. The mixed lymphoid progenitor gives rise to B and T lymphocytes and to natural killer cells. A granulocyte/monocyte progenitor gives rise to progenitors for monocytes, neutrophils, eosinophils, basophils and mast cells. The erythroid progenitors are also termed BFU-E and CFU-E. BFU-E, burst-forming unit erythroid; CFU-E, colony-forming unit erythroid.

In the haemopoietic hierarchy, the pluripotent stem cell gives rise to a mixed erythroid and megakaryocyte progenitor, which then divides into separate erythroid and megakaryocyte progenitors. The pluripotent stem cell also gives rise to a mixed lymphoid, granulocyte and monocyte progenitor, which divides into a progenitor of granulocytes and monocytes and a mixed lymphoid progenitor, from which B- and T-cell lymphocytes and natural killer (NK) cells develop (Fig. 1.2). The spleen, lymph nodes and thymus are secondary sites of lymphocyte production (see Chapter 9).

The stem cell has the capability for self-renewal (Fig. 1.3), so that...

Table of contents

• Cover
• Title Page
• Copyright
• Preface to the Eighth Edition
• Preface to the First Edition
• How to use your textbook
• About the companion website
• Chapter 1 Haemopoiesis
• Chapter 2 Erythropoiesis and general aspects of anaemia
• Chapter 3 Hypochromic anaemias
• Chapter 4 Iron overload
• Chapter 5 Megaloblastic anaemias and other macrocytic anaemias
• Chapter 6 Haemolytic anaemias
• Chapter 7 Genetic disorders of haemoglobin
• Chapter 8 The white cells, part 1: granulocytes, monocytes and their benign disorders
• Chapter 9 The white cells, part 2: lymphocytes and their benign disorders
• Chapter 10 The spleen
• Chapter 11 The aetiology and genetics of haematological neoplasia
• Chapter 12 Management of haematological malignancy
• Chapter 13 Acute myeloid leukaemia
• Chapter 14 Chronic myeloid leukaemia
• Chapter 15 Myeloproliferative neoplasms
• Chapter 16 Myelodysplastic syndromes
• Chapter 17 Acute lymphoblastic leukaemia
• Chapter 18 The chronic lymphocytic leukaemias
• Chapter 19 Hodgkin lymphoma
• Chapter 20 Non-Hodgkin lymphomas
• Chapter 21 Multiple myeloma and related plasma cell neoplasms
• Chapter 22 Aplastic anaemia and bone marrow failure
• Chapter 23 Haemopoietic stem cell transplantation
• Chapter 24 Platelets, blood coagulation and haemostasis
• Chapter 25 Bleeding disorders caused by vascular and platelet abnormalities
• Chapter 26 Coagulation disorders
• Chapter 27 Thrombosis 1: pathogenesis and diagnosis
• Chapter 28 Thrombosis 2: treatment
• Chapter 29 Haematological changes in systemic diseases
• Chapter 30 Blood transfusion
• Chapter 31 Pregnancy and neonatal haematology
• Appendix
• Index
• End User License Agreement